Aterovax Overview
- Founded
-
2006
- Status
-
Out of Business
- Employees
-
5
- Latest Deal Type
-
Out of Business
Aterovax General Information
Description
Developer of diagnostic products for the treatment of atherosclerosis. The company develops diagnostic tests for cardiovascular risk prediction by assessing the level of patients' atherosclerosis plaque development.
Contact Information
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Diagnostic Equipment
Medical Supplies
Primary Office
- Pepiniere paris Sante Cochin
- 29 rue du Faubourg Saint-Jacques
- 75014 Paris
- France
Aterovax Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Out of Business | 01-Apr-2016 | 00.000 | Completed | Out of Business | ||
| 3. Later Stage VC | 12-May-2013 | 00.000 | 00.000 | Completed | Generating Revenue | |
| 2. Grant | 26-Jul-2008 | $2.29M | $3.8M | Completed | Startup | |
| 1. Seed Round | 01-Jul-2006 | $3.8M | $3.8M | Completed | Startup |
Aterovax Patents
Aterovax Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2246440-A1 | Enzymatic assay for the quantitative determination of phospholipase a1 or a2 activity in a sample | Inactive | 29-Apr-2009 | 00000000 | 0 |
| EP-2249156-A1 | Enzymatic assay for the quantitative determination of phospholipase a1 or a2 activity in a sample based on the use of a solid phase coated with a fluorochrome-labelled substrate | Inactive | 29-Apr-2009 | 00000000 | 0 |
| CA-2751962-A1 | Enzymatic assay for the quantitative determination of phospholipase a1 or a2 activity in a sample | Inactive | 10-Feb-2009 | 00000000 | |
| EP-2396420-A1 | Enzymatic assay for the quantitative determination of phospholipase a1 or a2 activity in a sample | Inactive | 10-Feb-2009 | 00000000 | |
| US-20110312006-A1 | Enzymatic assay for the quantitative determination of phospholipase a1 or a2 activity in a sample | Inactive | 10-Feb-2009 | C12Q1/44 |
Aterovax Executive Team (8)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Gerald Ulrich Ph.D | Chief Operative Officer | ||
| Emmanuel Valentin Ph.D | Head & Director, Research & Development |
Aterovax Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| Antoine Ferry MD | Self | Board Member | 000 0000 |
| Eric Viaud | Self | Board Member | 000 0000 |
Aterovax Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
